>> But I guess I'm just surprised that companies don't collect the data from the sites, anonymize it and have it blinded / reviewed independently so as not to fool themselves.
Few if any company do that today unless data are intended for regulatory submission, thus eventually data quality falls to company review, more often than not, speed is priority in the field of oncology today, which presents special challenge for IO combination development that typically takes longer time than monotherapy.
News 
Market Data 
Discover 
